Phaseline

Companies › Monopar Therapeutics

Monopar Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MNPR-101-DFO*-89Zr
Humanized IgG1 monoclonal antibody against PD-L1, conjugated to Zirconium-89 radioisotope
–Phase 1Solid Tumor, AdultDec 2026
MNPR-101-PCTA-177Lu
Lutetium-177 labeled radiopharmaceutical targeting MNPR-101 antigen
–Phase 1Solid Tumor, AdultJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06337084MNPR-101-DFO*-89ZrPhase 1Solid Tumor, AdultOncologyDec 2026
NCT06617169MNPR-101-PCTA-177LuPhase 1Solid Tumor, AdultOncologyJan 2027

From the company's SEC filings

Cash and short-term investments of $105m on 2026-06-30; operating cash outflow about $14m a year; runway about 93 months at that burn, to Mar 2034

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.